In mouse models of pulmonary fibrosis, TD139, a Gal‐3 inhibitor with a strong affinity for the carbohydrate recognition domain of Gal‐3, has demonstrated effectiveness.90, 91. Here, LGALS3 is linked to pulmonary fibrosis.